Fig. 2.

LRG1 was an independent prognostic factor in the JANUS II cohort. (A) Tukey boxplot illustrating serum distribution of LRG1 grouped according to the NCCN risk criteria. Filled and open circles illustrate the PCa-specific mortality status at the last FU (median 6.8 yr, [IQR 2.5–7.7]). Significant differences were assessed by MWU testing. (B) Kaplan-Meier survival analysis and log-rank testing of prostate cancer–specific survival (PCSS) of patients grouped by LRG1 concentrations (tertiles: <26 μg/mL [first/low], 26–37 μg/mL [second/inter], and  ≥38 μg/mL [third/high]). (C) Time-dependent c-index for PCSS. Metastasis (blue) was included as a covariate in the clinical model and supplemented with PSA (blue, dashed) or LRG1 (orange). (D) Time-dependent decision curve analyses of combining LRG1 and metastasis for predicting PCSS within the first 3 yr after diagnosis.

AUC = area under the curve; CI = confidence interval; HR = hazard ratio; cont. = continuous; IQR = interquartile range; LRG1 = leucine-rich α-2-glycoprotein 1; Met = metastasis; MWU = Mann-Whitney U test; NCCN = National Comprehensive Cancer Network; PCa = prostate cancer; PSA = prostate-specific antigen; Ref. = reference.